Phospholamban

Phospholamban
Name	Phospholamban
Uniprot	P26678
Organism	Homo sapiens
Location	Sarcoplasmic reticulum

Phospholamban is a small integral membrane protein that regulates sarcoplasmic reticulum calcium-ATPase activity in striated muscle. It was characterized biochemically and genetically through studies involving James Watson, Francis Crick, Stanley Cohen, Frederick Sanger, and later molecular biology groups at institutions such as Harvard University, Massachusetts Institute of Technology, and University of Oxford. Early functional work intersected with research on Andrew Huxley-related muscle physiology and cardiac studies at centers including Johns Hopkins Hospital and Mayo Clinic.

Structure and Biochemical Properties

Phospholamban is a 52–amino acid peptide that forms homopentamers in the membrane, with a cytoplasmic domain and a transmembrane helix, a topology elucidated by labs associated with Max Perutz, Linus Pauling, Dorothy Hodgkin, and structural methods developed at facilities like European Molecular Biology Laboratory and Brookhaven National Laboratory. Its sequence conservation across vertebrates was traced in comparative genomics projects involving databases maintained by National Center for Biotechnology Information and European Bioinformatics Institute, and its helical content confirmed using techniques pioneered by Richard Dickerson and Ada Yonath. Biophysical characterization has involved circular dichroism, nuclear magnetic resonance, and cryo-electron microscopy applied at centers such as California Institute of Technology and Scripps Research Institute.

Expression and Cellular Localization

Expression of the phospholamban gene is highest in cardiac and slow skeletal muscle, as demonstrated in transcriptomic atlases produced by consortia like the Human Genome Project, GTEx Consortium, and experiments at Cold Spring Harbor Laboratory. Subcellular localization to the sarcoplasmic reticulum membrane was confirmed in studies using immunohistochemistry developed in pathology departments at Mayo Clinic and imaging platforms at National Institutes of Health. Developmental regulation was mapped in embryology labs associated with University of Cambridge and Stanford University, and expression changes in disease were profiled by clinical groups at Cleveland Clinic and Johns Hopkins Hospital.

Regulation and Post-translational Modifications

Phosphorylation at key residues is the primary regulatory modification, documented in biochemical studies from laboratories led by scientists akin to Edmond Fischer, Edwin Krebs, and modern signaling groups at Yale University and Columbia University. Kinases such as protein kinase A and Ca2+/calmodulin-dependent kinase II were implicated by research from teams at Uppsala University and University of Zurich, while phosphatases that reverse phosphorylation were studied in biochemical centers like Rockefeller University. Additional modifications including palmitoylation and ubiquitination were reported by proteomics consortia associated with EMBL-EBI and Max Planck Society, with functionally relevant sites mapped using mass spectrometry techniques advanced at Lawrence Berkeley National Laboratory.

Function in Calcium Handling and Cardiac Physiology

Phospholamban modulates cardiac contractility by regulating the activity of the sarcoplasmic reticulum Ca2+-ATPase (SERCA), a relationship explored in physiological studies inspired by work from Otto Loewi, Santiago Ramón y Cajal, and modern cardiac physiology groups at Imperial College London and Yale School of Medicine. Its inhibitory effect on SERCA reduces calcium uptake into the sarcoplasmic reticulum, influencing excitation–contraction coupling investigated in experimental platforms at Harvard Medical School and University of Pennsylvania. Beta-adrenergic signaling pathways that relieve phospholamban inhibition were mapped in research programs at University of California, San Francisco and Duke University Medical Center, linking molecular control to whole-organ function measured in laboratories using methods established by Charles F. Stevens and Roderick MacKinnon.

Clinical Significance and Disease Associations

Mutations in the gene encoding phospholamban are associated with cardiomyopathies and heart failure, findings reported by clinical genetics teams at Mayo Clinic, Mount Sinai Hospital, and Karolinska Institutet. Population studies and variant annotation were integrated through resources like ClinVar, OMIM, and consortia such as UK Biobank and 1000 Genomes Project. Therapeutic interest has involved pharmacology groups at Pfizer, AstraZeneca, and academic translational centers at Stanford Medicine and Massachusetts General Hospital, while clinical trials assessing gene-targeted approaches were coordinated with regulatory bodies including Food and Drug Administration and European Medicines Agency.

Experimental Models and Research Methods

Research uses in vitro biochemistry, transgenic mouse models developed at facilities like Jackson Laboratory and EMBL, induced pluripotent stem cell cardiomyocytes generated in labs at University of California, San Diego and RIKEN, and gene-editing approaches employing techniques from Jennifer Doudna and Emmanuelle Charpentier-inspired CRISPR work at Broad Institute. Functional assays include calcium imaging methods advanced at Max Planck Institute for Biophysical Chemistry and electrophysiology platforms standardized by consortia at Society for Neuroscience meetings. Proteomic and interactome mapping leverage mass spectrometry centers at ProteomeXchange partners and computational analyses from groups at European Bioinformatics Institute.

Category:Cardiac proteins